Positive News SentimentPositive NewsNASDAQ:ALT Altimmune (ALT) Stock Forecast, Price & News $4.04 +0.04 (+1.00%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$3.98▼$4.1650-Day Range$3.87▼$5.9752-Week Range$3.82▼$23.49Volume2.16 million shsAverage Volume1.78 million shsMarket Capitalization$199.13 millionP/E RatioN/ADividend YieldN/APrice Target$26.14 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Altimmune MarketRank™ ForecastAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside547.1% Upside$26.14 Price TargetShort InterestBearish17.95% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$80,630 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.77) to ($2.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.04 out of 5 starsMedical Sector610th out of 1,006 stocksPharmaceutical Preparations Industry302nd out of 492 stocks 3.4 Analyst's Opinion Consensus RatingAltimmune has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.14, Altimmune has a forecasted upside of 547.1% from its current price of $4.04.Amount of Analyst CoverageAltimmune has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted17.95% of the outstanding shares of Altimmune have been sold short.Short Interest Ratio / Days to CoverAltimmune has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Altimmune has recently decreased by 2.10%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAltimmune does not currently pay a dividend.Dividend GrowthAltimmune does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALT. Previous Next 2.7 News and Social Media Coverage News SentimentAltimmune has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.Search InterestOnly 18 people have searched for ALT on MarketBeat in the last 30 days. This is a decrease of -74% compared to the previous 30 days.MarketBeat FollowsOnly 10 people have added Altimmune to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Altimmune insiders have bought more of their company's stock than they have sold. Specifically, they have bought $80,630.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.19% of the stock of Altimmune is held by insiders.Percentage Held by Institutions93.69% of the stock of Altimmune is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Altimmune are expected to decrease in the coming year, from ($1.77) to ($2.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Altimmune is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Altimmune is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAltimmune has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Altimmune (NASDAQ:ALT) StockAltimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.Read More Receive ALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Altimmune and its competitors with MarketBeat's FREE daily newsletter. Email Address ALT Stock News HeadlinesMay 17, 2023 | americanbankingnews.comAltimmune, Inc. (NASDAQ:ALT) Forecasted to Post Q2 2023 Earnings of ($0.44) Per ShareMay 17, 2023 | americanbankingnews.comAltimmune, Inc. (NASDAQ:ALT) Short Interest Down 8.3% in AprilJune 1, 2023 | Behind the Markets (Ad)"How war impacts the stock market"Russia's invasion of Ukraine has already sent the stock market down 10%. But that's just the opening act for the new Russia-China Alliance. There's a major event involving China that's heating up... and it could boil over as soon as April 16th, 2023. Click Here to Learn How to Protect Your RetirementMay 16, 2023 | msn.comHC Wainwright & Co. Reiterates Altimmune (ALT) Buy RecommendationMay 12, 2023 | msn.comJMP Securities Reiterates Altimmune (ALT) Market Outperform RecommendationMay 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ginkgo Bioworks Holdings (DNA) and Altimmune (ALT)May 11, 2023 | msn.comAltimmune: Q1 Earnings InsightsMay 11, 2023 | finanznachrichten.deAltimmune, Inc: Altimmune Announces First Quarter 2023 Financial Results and Provides a Business UpdateJune 1, 2023 | Behind the Markets (Ad)[BREAKING] Small Firm Develops World's First Anti-Aircraft LaserSmall cap wins $1.65 billion contract to make them. GlobeNewswire says this is a $51.1 Billion market by 2026. See why this stock could soar 2,476% >>>May 11, 2023 | msn.comAltimmune: A Story, It Seems, Of Too Little Too LateMay 11, 2023 | finance.yahoo.comAltimmune Announces First Quarter 2023 Financial Results and Provides a Business UpdateMay 11, 2023 | americanbankingnews.comAnalysts Set Altimmune, Inc. (NASDAQ:ALT) Price Target at $26.00May 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Altimmune (ALT) and Nuwellis (NUWE)May 10, 2023 | marketwatch.comNovel Coronavirus (COVID-19) Vaccine Market Size and Gross Margin: Latest Insights | 2031May 4, 2023 | finance.yahoo.comAltimmune to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023April 24, 2023 | finance.yahoo.comAltimmune, Inc. (ALT) Stock Historical Prices & Data - Yahoo FinanceApril 16, 2023 | americanbankingnews.comAltimmune, Inc. (NASDAQ:ALT) Receives $26.00 Average PT from AnalystsApril 14, 2023 | markets.businessinsider.comB.Riley Financial Reaffirms Their Buy Rating on Altimmune (ALT)April 11, 2023 | finance.yahoo.comAltimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell™, an Immunotherapeutic for Chronic Hepatitis BApril 4, 2023 | americanbankingnews.comJMP Securities Reiterates "Market Outperform" Rating for Altimmune (NASDAQ:ALT)April 3, 2023 | americanbankingnews.comAltimmune's (ALT) "Market Outperform" Rating Reiterated at JMP SecuritiesApril 2, 2023 | markets.businessinsider.com7 Analysts Have This to Say About AltimmuneApril 1, 2023 | americanbankingnews.comAltimmune, Inc. (NASDAQ:ALT) Short Interest Up 16.0% in MarchMarch 30, 2023 | americanbankingnews.comAltimmune, Inc. (NASDAQ:ALT) Director Acquires $38,430.00 in StockMarch 29, 2023 | americanbankingnews.comDavid Drutz Acquires 9,000 Shares of Altimmune, Inc. (NASDAQ:ALT) StockMarch 27, 2023 | finance.yahoo.comAltimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of DirectorsMarch 25, 2023 | americanbankingnews.comMatthew Scott Harris Purchases 10,000 Shares of Altimmune, Inc. (NASDAQ:ALT) StockSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Altimmune and its competitors with MarketBeat's FREE daily newsletter. Email Address ALT Company Calendar Last Earnings5/11/2023Today5/31/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALT CUSIPN/A CIK1326190 Webaltimmune.com Phone(240) 654-1450Fax410-269-2601Employees47Year FoundedN/APrice Target and Rating Average Stock Price Forecast$26.14 High Stock Price Forecast$50.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+547.1%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-84,710,000.00 Net Margins-2,618.74% Pretax Margin-2,624.67% Return on Equity-45.37% Return on Assets-41.18% Debt Debt-to-Equity RatioN/A Current Ratio11.58 Quick Ratio11.58 Sales & Book Value Annual Sales$4.41 million Price / Sales45.15 Cash FlowN/A Price / Cash FlowN/A Book Value$3.40 per share Price / Book1.19Miscellaneous Outstanding Shares49,290,000Free Float47,720,000Market Cap$199.13 million OptionableOptionable Beta-0.08 Key ExecutivesVipin K. GargPresident, Chief Executive Officer & DirectorRichard I. EisenstadtSecretary, Chief Financial & Accounting OfficerM. Scot RobertsChief Scientific OfficerBertrand GeorgesChief Technology OfficerM. Scott HarrisChief Medical OfficerKey CompetitorsImmuneeringNASDAQ:IMRXBioVieNASDAQ:BIVIXOMANASDAQ:XOMAKezar Life SciencesNASDAQ:KZRRani TherapeuticsNASDAQ:RANIView All CompetitorsInsiders & InstitutionsArete Wealth Advisors LLCBought 28,427 shares on 5/22/2023Ownership: 0.058%JPMorgan Chase & Co.Sold 103,013 shares on 5/18/2023Ownership: 0.154%Geode Capital Management LLCBought 43,479 shares on 5/16/2023Ownership: 0.979%Silvercrest Asset Management Group LLCBought 41,000 shares on 5/16/2023Ownership: 0.210%AQR Capital Management LLCBought 21,662 shares on 5/16/2023Ownership: 0.044%View All Insider TransactionsView All Institutional Transactions ALT Stock - Frequently Asked Questions Should I buy or sell Altimmune stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Altimmune in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALT shares. View ALT analyst ratings or view top-rated stocks. What is Altimmune's stock price forecast for 2023? 7 Wall Street research analysts have issued 1 year price targets for Altimmune's stock. Their ALT share price forecasts range from $6.00 to $50.00. On average, they predict the company's stock price to reach $26.14 in the next twelve months. This suggests a possible upside of 547.1% from the stock's current price. View analysts price targets for ALT or view top-rated stocks among Wall Street analysts. How have ALT shares performed in 2023? Altimmune's stock was trading at $16.45 on January 1st, 2023. Since then, ALT stock has decreased by 75.4% and is now trading at $4.04. View the best growth stocks for 2023 here. When is Altimmune's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our ALT earnings forecast. How were Altimmune's earnings last quarter? Altimmune, Inc. (NASDAQ:ALT) announced its quarterly earnings data on Thursday, May, 11th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.09. The firm had revenue of $0.02 million for the quarter. Altimmune had a negative trailing twelve-month return on equity of 45.37% and a negative net margin of 2,618.74%. What ETFs hold Altimmune's stock? ETFs with the largest weight of Altimmune (NASDAQ:ALT) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), ETFMG Treatments Testing and Advancements ETF (GERM), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Future Gen 200 ETF (QQQS), ALPS Medical Breakthroughs ETF (SBIO), Invesco DWA SmallCap Momentum ETF (DWAS) and When did Altimmune's stock split? Shares of Altimmune reverse split on Friday, September 14th 2018. The 1-30 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Altimmune own? Based on aggregate information from My MarketBeat watchlists, some companies that other Altimmune investors own include Vaxart (VXRT), Pfizer (PFE), Verizon Communications (VZ), Amarin (AMRN), Advanced Micro Devices (AMD), Albireo Pharma (ALBO), Alliance Data Systems (ADS), AcelRx Pharmaceuticals (ACRX), Albertsons Companies (ACI) and Achieve Life Sciences (ACHV). What is Altimmune's stock symbol? Altimmune trades on the NASDAQ under the ticker symbol "ALT." Who are Altimmune's major shareholders? Altimmune's stock is owned by a number of retail and institutional investors. Top institutional investors include State Street Corp (10.06%), Ardsley Advisory Partners LP (2.94%), BlackRock Inc. (2.83%), Two Sigma Investments LP (2.12%), Two Sigma Advisers LP (1.93%) and Dimensional Fund Advisors LP (1.15%). Insiders that own company stock include David Drutz, Diane Jorkasky, Klaus Schafer, M Scot Roberts, Matthew Scott Harris, Philip Hodges, Venrock Healthcare Capital Par, Vipin K Garg and Wayne Pisano. View institutional ownership trends. How do I buy shares of Altimmune? Shares of ALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Altimmune's stock price today? One share of ALT stock can currently be purchased for approximately $4.04. How much money does Altimmune make? Altimmune (NASDAQ:ALT) has a market capitalization of $199.13 million and generates $4.41 million in revenue each year. The company earns $-84,710,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis. How can I contact Altimmune? Altimmune's mailing address is 910 CLOPPER ROAD SUITE 201S, GAITHERSBURG MD, 20878. The official website for the company is altimmune.com. The company can be reached via phone at (240) 654-1450, via email at arr@lifesciadvisors.com, or via fax at 410-269-2601. This page (NASDAQ:ALT) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.